VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION - ENDOTHELIN-2

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515928-36-00

Acronym

2018/0350/HP

Enrollment

Registered

2024-08-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncontrolled arterial hypertension

Brief summary

8-week change in amplitude of endothelium-dependent radial artery dilatation with sustained increase in blood flow

Detailed description

8 week change in peripheral and central arterial pressures and arterial stiffness, 8-week change in local concentrations of NO, EETs and ET-1 with sustained increase in blood flow, Variation in 8 weeks of natriuresis and measured glomerular filtration rate (DTPA labeled by the technetium 99m)

Interventions

DRUGBOSENTAN VIATRIS 125 mg

DRUGcomprimé pelliculé

DRUGBOSENTAN VIATRIS 62

DRUG5 mg

DRUGCellulose microcristalline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
8-week change in amplitude of endothelium-dependent radial artery dilatation with sustained increase in blood flow	—

Secondary

Measure	Time frame
8 week change in peripheral and central arterial pressures and arterial stiffness, 8-week change in local concentrations of NO, EETs and ET-1 with sustained increase in blood flow, Variation in 8 weeks of natriuresis and measured glomerular filtration rate (DTPA labeled by the technetium 99m)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026